THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE (7)(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014)
Company secures exclusive rights to incorporate the WIMAGINE BCI into its ARC-BCI™ System
WIMAGINE BCI has 7-year human safety data
Deal provides opportunity for ONWARD to be first-to-market with a BCI-enabled system to restore thought-driven movement after paralysis
EINDHOVEN, the Netherlands, Oct. 15, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord injury (SCI), today announces that it has signed an exclusive license with CEA to develop and commercialize the investigational WIMAGINE BCI designed by Clinatec as part of its investigational ARC-BCI System to restore thought-driven movement and function of the human body.
“Securing exclusive rights to the WIMAGINE BCI gives us an opportunity to be first to market with a BCI-enabled system to restore thought-driven movement after paralysis”, said ONWARD Medical CEO Dave Marver. “Clinatec is a world-renowned biomedical research institute and its BCI is ideal for our applications. We can now develop a truly integrated system that is well suited for the type of study required to gain regulatory approval and bring a BCI-enabled system to market,”
The ONWARD ARC-BCI System combines the WIMAGINE BCI from CEA with investigational ONWARD ARC-IM® Therapy (targeted implanted spinal cord stimulation) to form a DigitalBridge™ designed to enable thought-driven movement after paralysis. The WIMAGINE BCI has 7 years of human safety data and ONWARD ARC-IM Therapy has now been applied in more than 30 study participants.